TRDA vs. ANL, LXRX, SLRN, OCS, CRBP, FULC, TBPH, LRMR, PEPG, and TVTX
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Adlai Nortye (ANL), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Oculis (OCS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC), Theravance Biopharma (TBPH), Larimar Therapeutics (LRMR), PepGen (PEPG), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical preparations" industry.
Adlai Nortye (NASDAQ:ANL) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
Entrada Therapeutics has a net margin of 14.42% compared to Entrada Therapeutics' net margin of 0.00%. Adlai Nortye's return on equity of 9.73% beat Entrada Therapeutics' return on equity.
In the previous week, Entrada Therapeutics had 9 more articles in the media than Adlai Nortye. MarketBeat recorded 9 mentions for Entrada Therapeutics and 0 mentions for Adlai Nortye. Adlai Nortye's average media sentiment score of 0.32 beat Entrada Therapeutics' score of -1.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
Adlai Nortye has higher earnings, but lower revenue than Entrada Therapeutics.
35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Adlai Nortye presently has a consensus target price of $30.00, indicating a potential upside of 135.29%. Entrada Therapeutics has a consensus target price of $21.00, indicating a potential upside of 37.08%. Given Entrada Therapeutics' higher probable upside, equities research analysts clearly believe Adlai Nortye is more favorable than Entrada Therapeutics.
Entrada Therapeutics received 7 more outperform votes than Adlai Nortye when rated by MarketBeat users. However, 100.00% of users gave Adlai Nortye an outperform vote while only 73.33% of users gave Entrada Therapeutics an outperform vote.
Summary
Entrada Therapeutics beats Adlai Nortye on 10 of the 12 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
